Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
Key takeaways
- NVO LLY The pharmaceutical industry is highly competitive and driven by innovation.
- Novo Nordisk was first to market with a GLP-1 weight-loss drug.
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
NVO LLY The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn t be on any clearer display than in the competition between Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in the newly created GLP-1 weight-loss space. While Eli Lilly looks like the winner right now, Novo Nordisk s Wegovy pill is performing better than expected. That s important, and it could turn the stock into a long-term buy for dividend lovers.
Novo Nordisk was first to market with a GLP-1 weight-loss drug. The only problem is that it couldn t keep up with the demand for its Wegovy shot. That allowed compounders to enter the U.S. market for the drug, limiting the company s growth opportunities. It also gave competitor Eli Lilly a big opening when it launched its own GLP-1 options, Mounjaro and Zepbound.
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »